STOCK TITAN

Erasca, Inc. - $ERAS STOCK NEWS

Welcome to our dedicated page for Erasca news (Ticker: $ERAS), a resource for investors and traders seeking the latest updates and insights on Erasca stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Erasca's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Erasca's position in the market.

Rhea-AI Summary
Erasca, Inc. (Nasdaq: ERAS) reported financial results for the fiscal quarter ended September 30, 2023, and provided updates on their clinical programs. The company dosed the first patient with naporafenib plus trametinib in their SEACRAFT-1 Phase 1b trial and identified promising activity in the HERKULES-3 signal-seeking study of ERAS-007 in combination with encorafenib and cetuximab in EC-naïve patients with BRAF-mutated colorectal cancer. The company's balance sheet shows a strong position with $344 million in cash, cash equivalents, and marketable securities as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Erasca, Inc. (Nasdaq: ERAS) will participate in investor conferences in November 2023, including Jefferies London Healthcare Conference and 6th Annual Evercore ISI HealthCONx Conference. Webcasts and one-on-one investor meetings are planned. The company focuses on therapies for RAS/MAPK pathway-driven cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
conferences
-
Rhea-AI Summary
Erasca, Inc. to participate in fireside chat at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
conferences
Rhea-AI Summary
Erasca, Inc. to participate in fireside chat and investor meetings at Morgan Stanley Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
conferences
-
Rhea-AI Summary
Erasca announces dosing of first patient in SEACRAFT-1 Phase 1b trial evaluating naporafenib and trametinib in RAS Q61X solid tumors. SEACRAFT-2 trial in NRAS-mutant melanoma to begin in H1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.09%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.92%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.18%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.44%
Tags
conferences
Erasca, Inc.

Nasdaq:ERAS

ERAS Rankings

ERAS Stock Data

320.71M
85.72M
20.34%
47.39%
5.85%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO

About ERAS

our mission at erasca is embedded in our name: to erase cancer in patients by creating a new generation of oncology drugs that we hope will not just treat, but actually cure. energized by recent scientific discoveries and advances in drugging various biological drivers of cancer, we are committed to solving oncology’s hardest problems. we have assembled a proven team and joined forces with world-class collaborators who embrace our ambitious goals.